title: Peripheral T-cell lymphoma.
abstract: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.
authors.affiliation: Yale Cancer Center, New Haven, CT, USA. francine.foss@yale.edu
authors.forename: Francine M
authors.initials: FM
authors.lastname: Foss
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D056572:Histone Deacetylase Inhibitors